Join to View Full Profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Dr. Palmer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
New York Medical CollegeClass of 2001
Certifications & Licensure
AZ State Medical License 2013 - 2026
WI State Medical License 2008 - 2013
NY State Medical License 2003 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
- Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Start of enrollment: 2021 Jan 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia.Muhammad Ali Khan, Jeanne Palmer
Clinical Lymphoma, Myeloma & Leukemia. 2025-05-01 - Collaborative large language models for automated data extraction in living systematic reviews.Muhammad Ali Khan, Umair Ayub, Syed Arsalan Ahmed Naqvi, Kaneez Zahra Rubab Khakwani, Zaryab Bin Riaz Sipra
Journal of the American Medical Informatics Association. 2025-04-01 - 3 citationsTP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, Saubia Fathima, Kebede H Begna
American Journal of Hematology. 2025-04-01
Press Mentions
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 11th, 2022- Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis with ThrombocytopeniaMarch 3rd, 2022
Fighting Leukemia Then Joining the TeamAugust 2nd, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
